Why is Nitrazepam prescribed
This medication is a hypnotic benzodiazepam,
prescribed for insomnia and management of infantile
When should Nitrazepam not be taken?
Contraindicted in patients with chronic obstructive pulmonary disease,severe liver disease myasthenia gravis
,increased eye pressure and hypersensitivity.
What is the dosage of Nitrazepam
Adult the recommeded dose is 5mg at bedtime,increase to 10mg if needed.
How should Nitrazepam be Taken
It comes as a tablet to take by mouth with or without food.
Warning and precaution for Nitrazepam
Caution should be exercised in patients who have uninterrupted sleep of 7-10 hours after ingestin of the dose,amnesia,elderly,children,depression.
It may cause dizziness or drowsiness,do not drive a car or operate machinary while taking this medication
Patient may develop with incresed risk of suicidal thoughts,depression,watch them carefully.
No Lacohol condumption.
Side Effects of Nitrazepam
Central Nervous system,Agitation,aggressiveness,amnesia,incoordination,confusion,delusion,disorientation,dizziness,fatigue,hallucination,hangover,headache,irritability,restlessness and sedation.
low blood pressure and palpitation
Pharmacotherapeutic group: Hypnotics and Sedatives, Benzodiazepine derivatives,
ATC Code: N05CD02
Nitrazepam is a benzodiazepine compound with sedative properties. It acts in 30 to 60 minutes to produce sleep lasting six to eight hours.
5.2 Pharmacokinetic properties
Nitrazepam is well absorbed with peak blood levels being achieved within two hours after administration. Two hours after administration, the concentration of nitrazepam in the cerebrospinal fluid is about 8% and after 36 hours approximately 16% of the concentration in the plasma. The cerebrospinal fluid concentration thus corresponds to the non-protein-bound fraction of active ingredient in the plasma.
The half-life of Nitrazepam is on average 24 hours. Steady-state levels are achieved within five days. Nitrazepam undergoes biotransformation to a number of metabolites none of which possesses significant clinical activity.
About 5 % of metabolites are excreted unchanged in the urine together with less than 10% each of the 7-amino and 7-acetylamino metabolites in the first 48 hours. In younger persons the volume of distribution is 2L/kg, in elderly patients the volume of distribution is greater and the mean elimination half-life rises to 40 hours.
5.3 Preclinical safety data
There is no pre-clinical data of relevance to a prescriber, which is additional to that already included in other sections of the Summary of Product Characteristics.